Psoriasis, biologic therapy, and the pandemic of the 21st century

Nogueira, Miguel; Vender, Ron; Torres, Tiago

http://hdl.handle.net/10400.16/2586

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Nogueira-2020-Psoriasis.pdf		219.16 KB	Adobe PDF	Download

Send Feedback

Authors

Nogueira, Miguel

Vender, Ron

Torres, Tiago

Abstract(s)

The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.

Keywords

COVID-19 SARS-CoV-2 biologic coronavirus; psoriasis

URI

http://hdl.handle.net/10400.16/2586

Citation

Nogueira M, Vender R, Torres T. Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs Context. 2020;9:2020-4-10. doi:10.7573/dic.2020-4-10